title: [Exon-dependent Subgroup-analysis of the Non-interventional REASON-Study: PFS and OS in EGFR-mutated NSCLC Patients Treated with Gefitinib or Chemotherapy].
abstract: OBJECTIVE
  To analyze the influence of the localization of mutations in the epidermal growth factor receptor (EGFR) gene on progression-free (PFS) and overall survival (OS) in patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC) treated with gefitinib (gef) or chemotherapy (CT) under real world conditions within the REASON study.
  
  
  METHODS
  Subgroups of pts with mutations in exon 19 (n = 141), 18/20 (n = 43), and 21 (n = 104) were analyzed for PFS and OS according to gef or CT treatment and compared using the log-rank test.
  
  
  RESULTS
  Pts with mutations in exon 19 and 18/20 treated with gef as first line therapy showed increased PFS and OS compared to CT. This increase was statistically significant in pts with exon 19 mutation (11.3 vs. 6.5 months), but was not found in pts with exon 21 mutation (9.1 vs. 9.3 months). Also, OS was significantly increased in patients with mutation in exon 19 treated with gef ever over all treatment lines compared to CT (21.8 vs. 10.6 months), whereas this was not found in pts with mutation in exon 21 (14.1 vs. 13.9 months).
  
  
  CONCLUSIONS
  Localization and nature of EGFR mutations influences gefitinib treatment outcomes under routine conditions and should therefore be analyzed in detail.
authors: Krankenhaus Martha-Maria Halle-Doelau, Klinik für Innere Medizin II, Halle.
authors: W
authors: W
authors: Schuette
authors: Pathologisches Institut Humboldt Universität Berlin.
authors: M
authors: M
authors: Dietel
authors: Internistische Onkologie der Thoraxtumoren, Thoraxklinik im Universitätsklinikum Heidelberg, Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research, Heidelberg.
authors: M
authors: M
authors: Thomas
authors: Innere Klinik (Tumorforschung), Ruhrlandklinik, Westdeutsches Tumorzentrum (WTZ), Essen, Universitätsklinikum Essen, Universität Duisburg-Essen.
authors: W
authors: W
authors: Eberhardt
authors: Pius-Hospital Oldenburg.
authors: F
authors: F
authors: Griesinger
authors: iOMEDICO AG, Freiburg.
authors: U
authors: U
authors: Zirrgiebel
authors: Medical Affairs, AstraZeneca, Wedel.
authors: S
authors: S
authors: Radke
authors: Pathologisches Institut Universitätsklinik Heidelberg.
authors: P
authors: P
authors: Schirmacher
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality; D018572:Disease-Free Survival; D066246:ErbB Receptors / Q000235:genetics; D005091:Exons / Q000235:genetics*; D005260:Female; D000077156:Gefitinib; D005819:Genetic Markers / Q000235:genetics; D020022:Genetic Predisposition to Disease / Q000453:epidemiology / Q000235:genetics; D005858:Germany; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D000071185:Pharmacogenomic Testing / Q000379:methods; D017354:Point Mutation / Q000235:genetics; D015995:Prevalence; D011799:Quinazolines / Q000627:therapeutic use*; D011832:Radiation Injuries; D015203:Reproducibility of Results; D012307:Risk Factors; D012680:Sensitivity and Specificity; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D005819:Genetic Markers; D011799:Quinazolines; C512478:EGFR protein, human; D066246:ErbB Receptors; D000077156:Gefitinib